ReNeuron Group plc (LSE: RENE.L) today announces that it has generated further positive pre-clinical efficacy data with its ReN001 stem cell therapy for stroke. These follow-on studies were undertaken in validated rodent models of stroke equivalent to those used in the original efficacy studies undertaken by the Company. The delivery method and implant location of the ReN001 cells in the brain were selected to mimic as far as possible the protocols that are likely to be followed in human clinical trials. Additionally, the ReN001 cells used in these follow-on studies were drawn from production lots manufactured to cGMP1 standard, equivalent to those that will be used in clinical trials. The follow-on studies were designed to test the effects of different cell doses on efficacy.
